Studies on chronic myeloid leukemia (CML) in the Gulf region are scarce, consisting of a survey and expert meeting that included 15 experts in 2023 which discussed CML diagnosis, testing, treatment objectives, toxicities, and discontinuation in the Gulf region. Most patients were reported to be in first-line therapy, and the most common treatments were imatinib/imatinib generic in first-line and dasatinib in second- and third-lines. Mutation analysis was not reported to be routinely performed at the time of diagnosis but rather in case of progression to accelerated/blast phase or any sign of loss of response. While all participants were aware that BCR-ABL should be monitored every three months during the first year of treatment, 10% reported monitoring BCR-ABL every six months in practice due to test cost and lab capability. The most important first-line therapy objective was “achievement of major molecular response” (MMR) in younger patients and “overall survival” in older ones. The most important treatment objectives were “MMR” and “early molecular response followed by prolongation of overall survival” in the short term and “treatment-free remission” in the long term. The current practices in CML in the Gulf region appear to be similar to global figures.
关于海湾地区慢性髓系白血病（CML）的研究较为有限，主要包括2023年一项涵盖15位专家的调研及专家会议，会议探讨了该地区CML的诊断、检测、治疗目标、毒性反应及治疗终止等问题。据报告，大多数患者处于一线治疗阶段，其中一线治疗最常用伊马替尼/伊马替尼仿制药，二线及三线治疗则多使用达沙替尼。突变分析在诊断时并未作为常规检测项目，而多在疾病进展至加速期/急变期或出现任何疗效丧失迹象时进行。尽管所有参与者均知晓在治疗第一年应每三个月监测一次BCR-ABL水平，但10%的专家表示在实际操作中因检测成本及实验室能力限制，改为每六个月监测一次。对于年轻患者，最重要的治疗目标是"实现主要分子学反应（MMR）"，而老年患者则以"总体生存期"为首要目标。短期最重要的治疗目标为"达到MMR"及"实现早期分子学反应并延长总体生存期"，长期目标则为"实现无治疗缓解"。当前海湾地区CML的临床实践情况与全球数据基本一致。
肿瘤(癌症)患者之家